Summary
7.88 0.78(10.92%)09/13/2024
Altimmune Inc (ALT)
Altimmune Inc (ALT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 10.92 | 11.38 | 14.25 | 10.86 | -34.73 | 171.84 | -76.91 | -69.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.88 | |
| Open | 7.14 | |
| High | 8.25 | |
| Low | 7.14 | |
| Volume | 4,763,660 | |
| Change | 0.78 | |
| Change % | 10.92 | |
| Avg Volume (20 Days) | 1,822,395 | |
| Volume/Avg Volume (20 Days) Ratio | 2.61 | |
| 52 Week Range | 2.09 - 14.84 | |
| Price vs 52 Week High | -46.93% | |
| Price vs 52 Week Low | 276.79% | |
| Range | -0.91 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 505 | |
| EBIDTA | -11,790,191 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 31.67 | |
| Book Value | 5.2830 | |
| Earnings Per Share | -2.1100 | |
| EPS Estimate Current Quarter | -0.3900 | |
| EPS Estimate Next Quarter | -0.4300 | |
| EPS Estimate Current Year | -2.4400 | |
| EPS Estimate Next Year | -2.7400 | |
| Diluted EPS (TTM) | -2.1100 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -23.2496 | |
| Return on asset (TTM) | -0.2131 | |
| Return on equity (TTM) | -0.4099 | |
| Revenue TTM | 3,445,404 | |
| Revenue per share TTM | 0.0870 | |
| Quarterly Revenue Growth (YOY) | -0.9460 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -25,324,291 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.7888 | |
| Revenue Enterprise Value | 51.1073 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 39,738,600 | |
| Shares Float | 31,319,111 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 5.94 | |
| Institutions (%) | 83.23 | |
09/12 11:50 EST - 247wallst.com
Five Top Obesity Stocks to Buy and Hold Long Term
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
Five Top Obesity Stocks to Buy and Hold Long Term
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
09/10 13:09 EST - globenewswire.com
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose tissue (VAT) at Week 48 has been corrected from 25.6% to 28.3% and the reduction of subcutaneous adipose tissue has been corrected from 20.1% to 19.5%. The revised release follows:
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose tissue (VAT) at Week 48 has been corrected from 25.6% to 28.3% and the reduction of subcutaneous adipose tissue has been corrected from 20.1% to 19.5%. The revised release follows:
09/10 11:00 EST - accesswire.com
ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024
LAS VEGAS, NV / ACCESSWIRE / September 10, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for August 2024. According to the company, ALT5's transaction volume exceeded US$192 million for the month of August 2024, which represents a year-over-year increase of 120% from the $87 million recorded in August 2023.
ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024
LAS VEGAS, NV / ACCESSWIRE / September 10, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for August 2024. According to the company, ALT5's transaction volume exceeded US$192 million for the month of August 2024, which represents a year-over-year increase of 120% from the $87 million recorded in August 2023.
09/10 07:45 EST - globenewswire.com
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain.
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain.
09/09 08:00 EST - accesswire.com
ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024
LAS VEGAS, NV / ACCESSWIRE / September 9, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced their participation in the upcoming iFX Bangkok Expo. ALT5 will be exhibiting through the 3 days of the show at the Centra Grand & Bangkok Convention Centre providing product demonstrations, solutions and general information to many of the 4,500+ attendees starting September 16th in booth #88.
ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024
LAS VEGAS, NV / ACCESSWIRE / September 9, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced their participation in the upcoming iFX Bangkok Expo. ALT5 will be exhibiting through the 3 days of the show at the Centra Grand & Bangkok Convention Centre providing product demonstrations, solutions and general information to many of the 4,500+ attendees starting September 16th in booth #88.
09/03 07:30 EST - globenewswire.com
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).
08/27 11:26 EST - seekingalpha.com
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Weight loss drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune's pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation rates and lacks sugar control, unlike rivals. Financially, Altimmune has a cash runway of five to six quarters, necessitating a likely dilution before their phase 3 trial completion.
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Weight loss drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune's pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation rates and lacks sugar control, unlike rivals. Financially, Altimmune has a cash runway of five to six quarters, necessitating a likely dilution before their phase 3 trial completion.
08/26 08:45 EST - accesswire.com
ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
LAS VEGAS, NV / ACCESSWIRE / August 26, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech leader specializing in blockchain-powered technologies for digital asset management, is pleased to announce the appointment of Peter Tassiopoulos as Chief Executive Officer. Concurrently, Tony Issac will transition to the role of President while continuing as Chairman of the Board.
ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
LAS VEGAS, NV / ACCESSWIRE / August 26, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech leader specializing in blockchain-powered technologies for digital asset management, is pleased to announce the appointment of Peter Tassiopoulos as Chief Executive Officer. Concurrently, Tony Issac will transition to the role of President while continuing as Chairman of the Board.
08/23 11:00 EST - accesswire.com
ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024
LAS VEGAS, NV / ACCESSWIRE / August 23, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced their participation in the upcoming SiGMA Budapest show. ALT5 will be exhibiting through the 3 days of the show at the Hungexpo Budapest Congress and Exhibition Centre Hall E providing product demonstrations, solutions and general information to many of the 17,000+ attendees starting September 2nd in booth B133.
ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024
LAS VEGAS, NV / ACCESSWIRE / August 23, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced their participation in the upcoming SiGMA Budapest show. ALT5 will be exhibiting through the 3 days of the show at the Hungexpo Budapest Congress and Exhibition Centre Hall E providing product demonstrations, solutions and general information to many of the 17,000+ attendees starting September 2nd in booth B133.
08/19 18:30 EST - accesswire.com
ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024
Q2 Fintech results only include the period commencing May 15, 2024, the date on which the ALT 5 Sigma acquisition closed, to June 30, 2024 LAS VEGAS, NV / ACCESSWIRE / August 19, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced financial results for its second fiscal quarter ended June 29, 2024. Fiscal Second Quarter 2024 Key Highlights- Fintech Revenues of $2.17 million (for the period from May 15 to June 29) Gross Profit of $1.1 million or 51% Net income from continuing operations of $589 thousand, as compared to $79 thousand for the same period last fiscal year Net income per basic and diluted common share of $0.07, as compared to $0.02 for the same period last fiscal year for continuing operations and $0.01 for discontinued operations Cash and cash equivalents of $5.75 million Stockholders' equity of $22.9 million "We are very pleased with the performance of ALT5 Sigma, particularly considering that our Q2 results reflect only about 45 days of combined operations since the transaction was completed mid-quarter," stated Tony Issac, CEO of ALT5 Sigma.
ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024
Q2 Fintech results only include the period commencing May 15, 2024, the date on which the ALT 5 Sigma acquisition closed, to June 30, 2024 LAS VEGAS, NV / ACCESSWIRE / August 19, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced financial results for its second fiscal quarter ended June 29, 2024. Fiscal Second Quarter 2024 Key Highlights- Fintech Revenues of $2.17 million (for the period from May 15 to June 29) Gross Profit of $1.1 million or 51% Net income from continuing operations of $589 thousand, as compared to $79 thousand for the same period last fiscal year Net income per basic and diluted common share of $0.07, as compared to $0.02 for the same period last fiscal year for continuing operations and $0.01 for discontinued operations Cash and cash equivalents of $5.75 million Stockholders' equity of $22.9 million "We are very pleased with the performance of ALT5 Sigma, particularly considering that our Q2 results reflect only about 45 days of combined operations since the transaction was completed mid-quarter," stated Tony Issac, CEO of ALT5 Sigma.
08/13 14:00 EST - investorplace.com
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.
08/13 08:30 EST - accesswire.com
ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024
LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for July 2024. According to the company, ALT5's transaction volume exceeded US$179 million for the month of July 2024, which represents a year-over-year increase of 114% from the $84 million recorded in July 2023.
ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024
LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for July 2024. According to the company, ALT5's transaction volume exceeded US$179 million for the month of July 2024, which represents a year-over-year increase of 114% from the $84 million recorded in July 2023.
08/11 09:00 EST - investorplace.com
The 7 Best Under $10 Stocks to Buy in August 2024
To understand the allure of buying the best stocks under $10, it's a good idea to go back to basics. A stock's price reflects how much you pay for one dollar of a company's earnings.
The 7 Best Under $10 Stocks to Buy in August 2024
To understand the allure of buying the best stocks under $10, it's a good idea to go back to basics. A stock's price reflects how much you pay for one dollar of a company's earnings.
08/10 09:03 EST - seekingalpha.com
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors-Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Seema Sheoran - Evercore Omari Baruti - Goldman Sachs William Wood - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Second Quarter 2024 Financial Results Conference Call.
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors-Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Seema Sheoran - Evercore Omari Baruti - Goldman Sachs William Wood - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Second Quarter 2024 Financial Results Conference Call.
08/09 08:46 EST - fool.com
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Weight loss treatments such as Ozempic, Wegovy, Mounjaro, and Zepbound are big players in the diabetes and obesity care markets. One risk of losing weight is shedding too much muscle mass.
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Weight loss treatments such as Ozempic, Wegovy, Mounjaro, and Zepbound are big players in the diabetes and obesity care markets. One risk of losing weight is shedding too much muscle mass.
08/08 07:00 EST - globenewswire.com
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH)
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH)
08/02 07:30 EST - fool.com
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight loss space.
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight loss space.
08/01 07:30 EST - globenewswire.com
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update.
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update.
07/30 21:00 EST - globenewswire.com
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Altimmune, Inc. (NASDAQ: ALT) on behalf of long-term stockholders following a class action complaint that was filed against Altimmune on May 6, 2024 with a Class Period from December 1, 2023 to April 26, 2024. Our investigation concerns whether the board of directors of Altimmune have breached their fiduciary duties to the company.
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Altimmune, Inc. (NASDAQ: ALT) on behalf of long-term stockholders following a class action complaint that was filed against Altimmune on May 6, 2024 with a Class Period from December 1, 2023 to April 26, 2024. Our investigation concerns whether the board of directors of Altimmune have breached their fiduciary duties to the company.
07/25 08:30 EST - accesswire.com
ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024
LAS VEGAS, NV / ACCESSWIRE / July 25, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for Q1 and Q2 2024 combined. According to the company, ALT5's transaction volume reached US$879 million for the first two quarters of 2024, ending June 30, 2024, which represents a year-over-year increase of 99%.
ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024
LAS VEGAS, NV / ACCESSWIRE / July 25, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for Q1 and Q2 2024 combined. According to the company, ALT5's transaction volume reached US$879 million for the first two quarters of 2024, ending June 30, 2024, which represents a year-over-year increase of 99%.